Evidence map›Paper›PMID 36533777›Full record

ArticleDiabetes/metabolism research and reviews2023

Reduced early response to SARS-CoV2 vaccination in people with type 1 and type 2 diabetes, a 6 months follow-up study: The CoVaDiab study I.

Luca D'Onofrio, Marta Fogolari, Rocco Amendolara, Antonio Siena, Riccardo De Fata, Flavio Davini, Lucia Coraggio, Carmen Mignogna, Chiara Moretti, Ernesto Maddaloni and 2 more

Abstract read
In one paragraph

Article in Diabetes/metabolism research and reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. How does geographical diversity shape vaccine efficacy?Clinical and experimental vaccine research · 2024
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Luca D'OnofrioDepartment of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.ORCID 0000-0003-3905-0139
Marta FogolariLaboratory Unit of Fondazione Policlinico Universitario Campus Bio-Medico di Roma, Rome, Italy.ORCID 0000-0002-0218-5884
Rocco AmendolaraDepartment of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.ORCID 0000-0001-8740-0549
Antonio SienaDepartment of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.
Riccardo De FataDepartment of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.
Flavio DaviniLaboratory Unit of Fondazione Policlinico Universitario Campus Bio-Medico di Roma, Rome, Italy.
Lucia CoraggioDepartment of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.
Carmen MignognaDepartment of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.
Chiara MorettiDepartment of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.
Ernesto MaddaloniDepartment of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.ORCID 0000-0003-3844-9463
Silvia AngelettiLaboratory Unit of Fondazione Policlinico Universitario Campus Bio-Medico di Roma, Rome, Italy.
Raffaella BuzzettiDepartment of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.ORCID 0000-0003-1490-6041

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDiabetes mellitus worsens the prognosis of SARS-CoV-2 infection, and vaccination has been the major tool for reducing the risk of hospitalisation, and mortality. The primary aim of this study was to evaluate the response to the SARS-CoV-2 vaccine in subjects with diabetes and controls. Differences between type 1 (T1D) and type 2 (T2D) diabetes and clinical determinants of vaccination response were also evaluated.

methods128 subjects with diabetes (60 with T1D and 62 with T2D) and 202 subjects acting as controls who completed a full vaccination cycle with two doses of mRNA vaccine were enroled. People with previous SARS-CoV-2 infection were excluded. Antibodies (Ab) directed against the spike protein of the SARS-CoV-2 were evaluated at one and 6 months after vaccination.

resultsIn the whole cohort, the Ab level was higher among women than in men (p = 0.011) and negatively correlated with age (rho = -0.155, p = 0.005). Subjects with diabetes showed decreased levels of Ab after one month compared to controls (1217[747-1887]BAU/mL vs. 1477[942-2556]BAU/mL, p = 0.002), even after correction for age and gender (p = 0.002). No difference was found between subjects with T1D and T2D. After 6 months, antibody levels significantly decreased in people with and without diabetes, with no differences between groups, although some subjects were lost at follow-up. In subjects with diabetes, only a significant correlation was found between Ab level and renal function (rho 0.190, p = 0.042).

conclusionsBoth T1D and T2D are associated with a reduced early response to vaccination. The serum concentration of Ab significantly reduced over time in both groups, highlighting the relevance of vaccination boosters independently of the presence of diabetes.

Indexed as

COVID-19Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2AntibodiesCOVID-19 VaccinesFemaleFollow-Up StudiesHumansMaleRNA, ViralSARS-CoV-2VaccinationAntibodiesCOVID-19 VaccinesRNA, Viralantibodiescovid-19diabetesSARS-CoV-2vaccine

Identifiers

PMID36533777
PMCPMC9877797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.